ChemoCentryx, Inc. (NASDAQ:CCXI) Expected to Announce Earnings of -$0.19 Per Share
Equities research analysts expect that ChemoCentryx, Inc. (NASDAQ:CCXI) will report ($0.19) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for ChemoCentryx’s earnings. ChemoCentryx reported earnings per share of ($0.22) during the same quarter last year, which suggests a positive year over year growth rate of 13.6%. The firm is scheduled to issue its next quarterly earnings results after the market closes on Tuesday, August 8th.
According to Zacks, analysts expect that ChemoCentryx will report full year earnings of ($0.72) per share for the current year, with EPS estimates ranging from ($0.85) to ($0.59). For the next year, analysts anticipate that the firm will report earnings of ($0.86) per share, with EPS estimates ranging from ($1.20) to ($0.51). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that that provide coverage for ChemoCentryx.
ChemoCentryx (NASDAQ:CCXI) last posted its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.14. The company had revenue of $8.23 million during the quarter.
Separately, Zacks Investment Research upgraded shares of ChemoCentryx from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a report on Monday, July 17th.
In related news, insider Petrus Bekker sold 76,013 shares of the company’s stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $9.95, for a total value of $756,329.35. Following the transaction, the insider now directly owns 65,963 shares in the company, valued at $656,331.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 223,649 shares of company stock worth $2,157,360 over the last 90 days. 26.80% of the stock is currently owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Bank of Montreal Can acquired a new position in ChemoCentryx during the second quarter valued at approximately $102,000. Trexquant Investment LP increased its position in ChemoCentryx by 81.1% in the second quarter. Trexquant Investment LP now owns 18,600 shares of the biopharmaceutical company’s stock valued at $174,000 after buying an additional 8,327 shares during the period. State of Wisconsin Investment Board acquired a new position in ChemoCentryx during the second quarter valued at approximately $178,000. Dynamic Technology Lab Private Ltd acquired a new position in ChemoCentryx during the first quarter valued at approximately $189,000. Finally, First Quadrant L P CA acquired a new position in ChemoCentryx during the second quarter valued at approximately $219,000. Institutional investors and hedge funds own 49.57% of the company’s stock.
ChemoCentryx (CCXI) remained flat at $10.39 during mid-day trading on Monday. The company’s stock had a trading volume of 144,419 shares. ChemoCentryx has a 52 week low of $3.95 and a 52 week high of $10.80. The firm’s 50-day moving average price is $9.21 and its 200 day moving average price is $7.62. The firm’s market cap is $500.52 million.
TRADEMARK VIOLATION WARNING: This report was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/08/07/chemocentryx-inc-nasdaqccxi-expected-to-announce-earnings-of-0-19-per-share.html.
ChemoCentryx Company Profile
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.